
Both primary and secondary endpoints were met in Lundbeck's phase IIIb trial, which goes under the name Deliver, of the migraine drug Vyepti, it reports in a press release on Monday morning.
The study investigated the effect of Vyepti as a treatment for patients with chronic or episodic migraines who have already tried preventive treatments two to four times with other older drugs, which have failed because of a lack of effect or intolerable side effects.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app